<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article article-type="research-article" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosntds</journal-id>
<journal-title-group>
<journal-title>PLOS Neglected Tropical Diseases</journal-title>
</journal-title-group>
<issn pub-type="epub">1935-2735</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pntd.0004592</article-id>
<article-id pub-id-type="publisher-id">PNTD-D-16-00085</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Infectious diseases</subject><subj-group><subject>Bacterial diseases</subject><subj-group><subject>Leprosy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Tropical diseases</subject><subj-group><subject>Neglected tropical diseases</subject><subj-group><subject>Leprosy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune physiology</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune physiology</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune system</subject><subj-group><subject>Innate immune system</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune system</subject><subj-group><subject>Innate immune system</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Developmental biology</subject><subj-group><subject>Molecular development</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene expression</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Blood cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject><subj-group><subject>Regulatory T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject><subj-group><subject>Regulatory T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject><subj-group><subject>Regulatory T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject><subj-group><subject>Regulatory T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Blood cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cell motility</subject><subj-group><subject>Chemotaxis</subject><subj-group><subject>Chemokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Spectrum analysis techniques</subject><subj-group><subject>Spectrophotometry</subject><subj-group><subject>Cytophotometry</subject><subj-group><subject>Flow cytometry</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Molecular biology</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>Cloning</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>Cloning</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Leprosy Reactions Show Increased Th17 Cell Activity and Reduced FOXP3+ Tregs with Concomitant Decrease in TGF-β and Increase in IL-6</article-title>
<alt-title alt-title-type="running-head">Imbalance of Th17/Treg in Leprosy Reactions</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Saini</surname>
<given-names>Chaman</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="fn" rid="currentaff001"><sup>¤a</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Siddiqui</surname>
<given-names>Anisuddin</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Ramesh</surname>
<given-names>Venkatesh</given-names>
</name>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Nath</surname>
<given-names>Indira</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="fn" rid="currentaff002"><sup>¤b</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>National Institute of Pathology (ICMR) Safdarjung Hospital Campus, New Delhi, India</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Government Autonomous Holkar Science College, Indore, India</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Department of Dermatology, Safdarjung Hospital New Delhi, India</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Johnson</surname>
<given-names>Christian</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Fondation Raoul Follereau, FRANCE</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con" id="contrib001">
<p>Conceived and designed the experiments: CS IN. Performed the experiments: CS VR. Analyzed the data: CS IN. Contributed reagents/materials/analysis tools: IN VR AS. Wrote the paper: CS IN. Clinical evaluation of leprosy patients: VR.</p>
</fn>
<fn fn-type="current-aff" id="currentaff001">
<label>¤a</label><p>Current address: Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India</p>
</fn>
<fn fn-type="current-aff" id="currentaff002">
<label>¤b</label><p>Current address: Retired, New Delhi, India</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">indiranath@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>1</day>
<month>4</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<month>4</month>
<year>2016</year>
</pub-date>
<volume>10</volume>
<issue>4</issue>
<elocation-id>e0004592</elocation-id>
<history>
<date date-type="received">
<day>20</day>
<month>1</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>9</day>
<month>3</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-year>2016</copyright-year>
<copyright-holder>Saini et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pntd.0004592"/>
<abstract>
<sec id="sec001">
<title>Background</title>
<p>50% of leprosy patients suffer from episodes of Type 1/ reversal reactions (RR) and Type 2/ Erythema Nodosum Leprosum (ENL) reactions which lead to morbidity and nerve damage. CD4<sup>+</sup> subsets of Th17 cells and CD25<sup>+</sup>FOXP3<sup>+</sup> regulatory T cells (Tregs) have been shown to play a major role in disease associated immunopathology and in stable leprosy as reported by us and others. The aim of our study was to analyze their role in leprosy reactions.</p>
</sec>
<sec id="sec002">
<title>Methodology and Principle Findings</title>
<p>Quantitative reverse transcribed PCR (qPCR), flowcytometry and ELISA were used to respectively investigate gene expression, cell phenotypes and supernatant levels of cytokines in antigen stimulated PBMC cultures in patients with stable disease and those undergoing leprosy reactions. Both types of reactions are associated with significant increase of Th17 cells and associated cytokines IL-17A, IL-17F, IL-21, IL-23 and chemokines CCL20, CCL22 as compared to matching stable forms of leprosy. Concurrently patients in reactions show reduction in FOXP3<sup>+</sup> Treg cells as well as reduction in TGF-β and increase in IL-6. Moreover, expression of many T cell markers, cytokines, chemokines and signaling factors were observed to be increased in RR as compared to ENL reaction patients.</p>
</sec>
<sec id="sec003">
<title>Conclusions</title>
<p>Patients with leprosy reactions show an imbalance in Th17 and Treg populations. The reduction in Treg suppressor activity is associated withhigherTh17cell activity. The combined effect of reduced TGF-β and enhanced IL-6, IL-21 cytokines influence the balance between Th17 or Treg cells in leprosy reactions as reported in the murine models and autoimmune diseases. The increase in Th17 cell associated cytokines may contribute to lesional inflammation.</p>
</sec>
</abstract>
<abstract abstract-type="summary">
<title>Author Summary</title>
<p>Reversal reactions (RR; Type 1) and Erythema Nodosum Leprosum (ENL; Type 2) are two types of leprosy reactions which appear episodically in a proportion of leprosy patients and lead to high morbidity and peripheral nerve damage that require immediate medical attention, ENL seen in anergic lepromatous patients, show immune complexes as well as transient emergence of T cell functions. Lesions of RR with borderline tuberculoid background show pathological features associated with delayed-type hypersensitivity. The present study shows increased Th17 cell show activity in reaction patients as compared to the matching stable leprosy type and which may contribute to the inflammation/immunopathology observed in the lesions. This increase is accompanied by reduction in Treg cells and their inhibitory activity. The balance between Th17 and Treg cells may be influenced by the combined effects of reduction in TGF-β and increase in IL-6, IL-21 cytokines. Of interest was the expression of more genes associated with T cells, cytokines, chemokines, signaling and transcription factors by RR as compared to ENL patient.</p>
</abstract>
<funding-group>
<funding-statement>The work submitted in the manuscript was supported by a grant received by IN (which has expired) received from The Department of Science and Technology, Ministry of Science and Technology, India, Grant number SR/SO/RFS-01/2009. CS thanks to Indian Council of Medical Research for senior research fellowship (80/916/2014-ECD-I). IN is now retired and has no institutional affiliation. The funders had no role in study design, data collection, analysis, decision to publish or preparation of manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="7"/>
<table-count count="5"/>
<page-count count="21"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec004" sec-type="intro">
<title>Introduction</title>
<p>Leprosy reactions occurring in approximately 50% of leprosy patients cause severe morbidity and need immediate clinical attention. Whereas the stable leprosy forms run a bland course amenable to multi drug therapy, leprosy reactions can be triggered by treatment and can also occur after the completion of treatment. Leprosy is a chronic infection of skin and peripheral nerves caused by <italic>Mycobacterium leprae</italic> and is of public health concern in India, South America, Central Africa and South East Asia. The global prevalence of leprosy was reported by WHO to be 180, 618 cases in 2014, while the number of new cases reported in the same year was 215,656[<xref ref-type="bibr" rid="pntd.0004592.ref001">1</xref>]. Research has been centered around the diverse clinico-pathological presentation of leprosy in man [<xref ref-type="bibr" rid="pntd.0004592.ref002">2</xref>], where the polar forms tend to remain stable whereas the borderline forms are vulnerable to reactions and morbidity. Tuberculoid leprosy presents as both polar (TT) and borderline (BT) forms with well defined an aesthetic skin patches which are paucibacillary and prone to early peripheral nerve damage. In contrast, the lepromatous forms of polar (LL) and borderline (BL) forms show diffuse involvement of skin and other organs with presence of varying load of the pathogen in macrophages, endothelial and Schwann cells. Leprosy reactions are mainly of 2 types, Type 1 or reversal reactions (RR) are seen in borderline leprosy forms of BT, BB and BL where there is inflammation localized to the dermal patch and the neighboring peripheral nerve[<xref ref-type="bibr" rid="pntd.0004592.ref003">3</xref>]. Acute neuritis is painful and is a major medical emergency which when unattended leads to nerve damage and deformity. On the other hand, Type 2 reaction specially ENL, appears in BL/LL patients who show systemic features accompanied by fever, joint pains and small reddish nodules scattered over the body along with peripheral nerve involvement. Patients at the tuberculoid and lepromatous poles show reverse patterns in cell mediated immunity and antibody responses to the <italic>M</italic>.<italic>leprae</italic> antigens and have been reported to be associated respectively with Th1, Th2 paradigm[<xref ref-type="bibr" rid="pntd.0004592.ref004">4</xref>] with some patients showing Th0 profile[<xref ref-type="bibr" rid="pntd.0004592.ref005">5</xref>]. The immune mechanisms underlying the exquisite antigen unresponsiveness in lepromatous leprosy and the leprosy reactions are yet to be fully understood. Leprosy reactions specially ENL have been shown to be associated with enhanced T cell activity, altered cytokine pattern and a Th1 shift[<xref ref-type="bibr" rid="pntd.0004592.ref006">6</xref>]. Immune complexes were seen both in the serum and tissues of ENL patients[<xref ref-type="bibr" rid="pntd.0004592.ref007">7</xref>]. The triggering factors in the inductions of these reactions are not known although motifs of LSR2protein of <italic>M</italic>.<italic>leprae</italic> have been shown to be recognized during ENL[<xref ref-type="bibr" rid="pntd.0004592.ref008">8</xref>].</p>
<p>In addition to the conventional CD4<sup>+</sup> subsets of Th1 and Th2 cells, additional subsets of Th17 and CD25<sup>+</sup>FOXP3<sup>+</sup>Tregulatory cells were discovered initially in models of autoimmunity[<xref ref-type="bibr" rid="pntd.0004592.ref009">9</xref>] followed subsequently in various human diseases including autoimmune states[<xref ref-type="bibr" rid="pntd.0004592.ref010">10</xref>] and infectious diseases caused by mycobacteria [<xref ref-type="bibr" rid="pntd.0004592.ref011">11</xref>], respiratory syncitial virus [<xref ref-type="bibr" rid="pntd.0004592.ref012">12</xref>] and HIV [<xref ref-type="bibr" rid="pntd.0004592.ref013">13</xref>]. CD4<sup>+</sup> Th17 cells have an important role in autoimmune inflammation, clearance of pathogens and tissue pathology [<xref ref-type="bibr" rid="pntd.0004592.ref014">14</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref015">15</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref016">16</xref>]. They produce IL-17A, IL-17F and IL-22 which lead to tissue inflammation and destruction [<xref ref-type="bibr" rid="pntd.0004592.ref017">17</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref018">18</xref>]. On the other hand Treg cells have a suppressor/inhibitory role and regulate inflammation[<xref ref-type="bibr" rid="pntd.0004592.ref019">19</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref020">20</xref>] and maintain tolerance[<xref ref-type="bibr" rid="pntd.0004592.ref009">9</xref>]. The differentiation pathways of these two subsets are influenced by various cytokines. TGF-β is essential for differentiating naive T cells towards Th17 cells[<xref ref-type="bibr" rid="pntd.0004592.ref021">21</xref>]. It acts in concert with the pro inflammatory cytokine IL-6 to induce the transcription factor RORC that leads to Th17 differentiation. Treg cells appear to retard the differentiation of Th17 cells [<xref ref-type="bibr" rid="pntd.0004592.ref022">22</xref>] where relative levels of TGF-β and IL-6 determine the outcome [<xref ref-type="bibr" rid="pntd.0004592.ref023">23</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref024">24</xref>].</p>
<p>Our and other studies had shown that CD4<sup>+</sup>FOXP3<sup>+</sup>T regulatory cells producing TGF-β were increased in stable lepromatous patients which may explain the anergy associated with this leprosy type [<xref ref-type="bibr" rid="pntd.0004592.ref025">25</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref026">26</xref>]. Moreover we reported that Th17 cells may constitute the third subset of Th cells in leprosy patients who failed to show Th1 and Th2 polarization[<xref ref-type="bibr" rid="pntd.0004592.ref027">27</xref>]. Others reported IL-17F increase may be an early marker of the reversal reactions[<xref ref-type="bibr" rid="pntd.0004592.ref028">28</xref>]. The present study is aimed at understanding the mechanisms that lead to immune inflammation and immune-regulation during leprosy reactions. We investigated patients suffering from both RR and ENL reactions and compared them with matching non reactive stable forms of BT and LL respectively. <italic>M</italic>.<italic>leprae</italic> (MLSA) stimulated PBMC from patients were investigated for gene expression by qPCR, flowcytometry for phenotype identity and ELISA for cytokine levels in culture supernatants.</p>
</sec>
<sec id="sec005" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="sec006">
<title>Ethics statement</title>
<p>Informed written consent for blood and skin biopsies was obtained from patients following approval of the study by the Institutional Ethical Committee [08-09-EC (3/7)] of Safdarjung Hospital, New Delhi, India.</p>
</sec>
<sec id="sec007">
<title>Patients</title>
<p>Sixty six newly diagnosed leprosy patients (44 males, 22 females aged between 19–60 years) attending the Leprosy Clinics of the Department of Dermatology, Safdarjung Hospital, New Delhi were included in the study (<xref ref-type="table" rid="pntd.0004592.t001">Table 1</xref>). Leprosy type was determined on the basis of clinical and histological criteria as per the Ridley-Jopling classification [<xref ref-type="bibr" rid="pntd.0004592.ref002">2</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref029">29</xref>]. The study group included 30 leprosy patients in reactions prior to institution of anti-reaction therapy: 15 each were in type 1/reversal reactions (RR) and type 2/Erythema Nodosum Leprosum (ENL); 36 freshly diagnosed patients with stable leprosy without previous history or clinical evidence of reactions were included as controls and consisted of 18 each of borderline tuberculoid (BT) and lepromatous (LL) leprosy. Exclusion criteria included patients below 18 years of age, pregnancy, clinical evidence of anemia and other infections such as tuberculosis, HIV and helminthic infestation. In this study antigen (MLSA) stimulated and unstimulated PBMC were investigated for i) gene expression in 10 BT, 9 BT with RR 10 LL, and 9 LL with ENL reactions ii) T cell phenotypes were identified with flow cytometry in 8 each of BT and LL subjects and 6 each of BT-RR and LL-ENL patients and iii) ELISA on selected cytokines was undertaken on PBMC culture supernatants of all four clinical groups.</p>
<table-wrap id="pntd.0004592.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0004592.t001</object-id>
<label>Table 1</label> <caption><title>Clinical details of 66 newly diagnosed untreated leprosy patients.</title></caption>
<alternatives>
<graphic id="pntd.0004592.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0004592.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Leprosy Type</th>
<th align="left">Patients</th>
<th align="left">Age</th>
<th align="left">Sex</th>
<th align="left"/>
<th align="left">Duration of disease</th>
<th align="left">Duration of reaction</th>
<th align="left">BI</th>
</tr>
<tr>
<th align="left"/>
<th align="left">No</th>
<th align="left">Range</th>
<th align="left">M</th>
<th align="left">F</th>
<th align="left">(months)</th>
<th align="left">(days)</th>
<th align="left"/>
</tr>
</thead>
<tbody>
<tr>
<td align="left">BT</td>
<td align="left">18</td>
<td align="left">19–48</td>
<td align="left">11</td>
<td align="left">7</td>
<td align="left">2–24</td>
<td align="left">-</td>
<td align="left">0–0.5</td>
</tr>
<tr>
<td align="left">BT-RR</td>
<td align="left">15</td>
<td align="left">22–48</td>
<td align="left">10</td>
<td align="left">5</td>
<td align="left">1–24</td>
<td align="left">8–180</td>
<td align="left">0–1.6</td>
</tr>
<tr>
<td align="left">LL</td>
<td align="left">18</td>
<td align="left">24–60</td>
<td align="left">12</td>
<td align="left">6</td>
<td align="left">6–15</td>
<td align="left">-</td>
<td align="left">5–6</td>
</tr>
<tr>
<td align="left">LL-ENL</td>
<td align="left">15</td>
<td align="left">22–60</td>
<td align="left">11</td>
<td align="left">4</td>
<td align="left">3–36</td>
<td align="left">8–28</td>
<td align="left">1.2–5.5</td>
</tr>
<tr>
<td align="left">Total</td>
<td align="left">66</td>
<td align="left">19–60</td>
<td align="left">44</td>
<td align="left">22</td>
<td align="left">1–36</td>
<td align="left">8–180</td>
<td align="left">0–6</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>Patients were typed on the basis of Ridley Jopling classification [<xref ref-type="bibr" rid="pntd.0004592.ref002">2</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref029">29</xref>], BI; Bacillary Index (mean of six lesional sites), M; male, F; female. Borderline Tuberculoid leprosy; (BT), Borderline Tuberculoid Reversal Reaction; (BT-RR), Lepromatous Leprosy; (LL), Erythema Nodosum Leprosum; (ENL), Bacterial Index; (BI)</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec008">
<title>Isolation of peripheral blood mononuclear cells (PBMC)</title>
<p>10 ml of venous blood was collected in heparinized sterile tubes (10 units/ml). PBMC were separated by density gradient centrifugation at 800g for 20 min on Ficoll-Hypaque (Histopaque, Sigma Aldrich, USA) as described earlier [<xref ref-type="bibr" rid="pntd.0004592.ref027">27</xref>]. Cells were washed three times in sterile 1x HBSS (GIBCO NY, USA) and re-suspended as described below. Cell viability by 0.2% trypan blue staining (Sigma Aldrich, MO, USA) ranged from 95–98%.</p>
</sec>
<sec id="sec009">
<title><italic>Ex vivo s</italic>timulation of PBMC cultures</title>
<p><italic>Ex vivo</italic> PBMC cultures were undertaken as described previously [<xref ref-type="bibr" rid="pntd.0004592.ref027">27</xref>]. In brief, 1.5x10<sup>6</sup> cells /ml suspended in RPMI 1640 (GIBCO NY, USA) with 10% pooled human AB serum, 2mM L-glutamine, 100 units of penicillin (Sigma Aldrich, MO, USA) and 100 μg streptomycin (Sigma Aldrich, MO, USA) were cultured in sterile flat bottom 24- well plates (Falcon, USA) as follows: cells were stimulated with and without 10 μg/ml of <italic>M</italic>. <italic>leprae</italic> sonicated antigen (MLSA) kindly provided by Dr. P J Brennan(Colorado State University, USA). Cultures were optimized for incubation in earlier studies [<xref ref-type="bibr" rid="pntd.0004592.ref027">27</xref>] to 48 h at 37°C in humidified 5% CO<sub>2</sub> + air. After incubation, harvested cells were washed as above and stored in RNA later (Sigma Aldrich, MO, USA) for gene expression studies or processed for flow cytometry analysis as given below.</p>
</sec>
<sec id="sec010">
<title>RNA isolation and reverse transcriptase PCR reaction</title>
<p>RNA was isolated from cultured PBMC and skin lesions using RNeasy Mini Kit (Qiagen, Maryland, USA) according to the manufacturer’s instructions. The isolated RNA was quantified using nanodrop spectrophotometer (Nanodrop Technologies, Wilmington, USA) and purity at 260/280 from 1.8 to 2.0 was considered to be optimum. The quality of RNA was also checked for 28s and 18s RNA by electropherogram using Bio analyzer (Agilent Technologies, Inc., Singapore). RNA Integration Number value of &gt;7 was considered to be optimum. For cDNA synthesis 1 μg total RNA was transcribed with RT First strand kit (SA Biosciences, MD, USA). Reactions were performed as per the manufacturer’s instructions and the cDNA stored at -20°C till further use.</p>
</sec>
<sec id="sec011">
<title>PCR array</title>
<p>This study employed a commercially customized PCR array for 84 genes (accession numbers of genes and primers were provided by PAHS 073, SA Biosciences, Qiagen Co. CA,USA, (<xref ref-type="supplementary-material" rid="pntd.0004592.s001">S1 Table</xref>) and used as per the manufacturer’s instructions and included primers for expression of genes for cell surface markers- CD28, CD34, CD3D, CD3E, CD3G, CD4, CD40LG, CD8, ICAM1, ICOS, ISG20, cytokines- CSF2, CSF3, IFN-γ, IL-10, IL-12B, IL-13, IL-15, IL-17A, IL-17C, IL-17D, IL-17F, IL-18, IL-1β, IL-2, IL-21, IL-22, IL-23A, IL-25, IL-27, IL-3, IL-4, IL-5, IL-6, TGF-β1, TNF, cytokine receptors-IL12RB1, IL12RB2, IL17RB, IL17RC, IL17RD, IL17RE, IL23R, IL6R, IL7R, chemokines- CCL1, CCL2, CCL20, CCL22, CCL7, CD247, CX3CL1, CXCL1, CXCL12, CXCL2, CXCL5, CXCL6, IL8, MMP13, MMP3, MMP9 signaling and transcription markers- CACYBP, CEBPB, CLEC7A, S1PR1, FOXP3, GATA3, JAK1, JAK2, NFATC2, NFKB1, RORC, SOCS1, SOCS3, STAT3, STAT4, STAT5A, STAT6, SYK, TBX21, TIRAP, TLR4, TRAF6, YY1: Housekeeping genes consisted of β2M, HPRT1, RPL13A, GAPDH, ACTB. It was ensured that the cDNA used had optical density (OD) &gt;1.7 at 260/280 wavelength. 1 μg of cDNA was used per reaction/ well containing the ready to use PCR master mix and appropriate primers. These were then subjected for 2 h to quantitative reverse transcribed PCR (qPCR, ABI 7000, Applied Biosystems Singapore)). Threshold cycle values were normalized and expressed as ΔCt: mean Ct of gene of interest-mean Ct of set of 5 housekeeping genes. Fold change in gene expression was calculated by 2-ΔΔCt method using manufacturer’s software. Heat maps showing level of expression of genes were visualized as magnitude/intensity of fluorescence using online software (<ext-link ext-link-type="uri" xlink:href="http://pcrdataanalysis.sabiosciences.com/" xlink:type="simple">pcrdataanalysis.sabiosciences.com</ext-link>) provided by SABiosciences, Qiagen. Patients with RR were compared with BT and ENL with LL.</p>
</sec>
<sec id="sec012">
<title>Flowcytometry analysis of cell surface and intracellular markers of PBMC cultures</title>
<p>All reagents were obtained from BD Biosciences, San Diego, CA and used as per manufacturer’s instructions as described earlier[<xref ref-type="bibr" rid="pntd.0004592.ref025">25</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref027">27</xref>]. 8 h prior to harvest, <italic>ex vivo</italic> cultured cells were incubated with monensin (BD Golgi Stop) to block secretion of cytokine. For surface staining, 0.5 x 10<sup>6</sup>cells/50 μl in staining buffer were incubated with a cocktail of anti human CD3 (Per-Cpcy-5.5, clone UCHT1), CD4 (APC-H7, Clone SK3), CD25 (FITC, clone M-A251) and CCR6 (PE-Cy7 clone) with respective isotype controls. After the surface staining, cells were washed two times and permeabilized with permeabilizing / fixation solution (containing saponin/paraformaldehyde) for 30 min at 4°C. The cells were washed as above and resuspended in Perm/Wash buffer and incubated with anti human IL-17A (Alexa Fluor-647, clone 64DEC17), IL-17F (Alexa Fluor-488, clone O33-782), IL-6 (PE, clone MQ2-6A3) and IL-21 (PE, clone-3A3-N2.1) at 4°C for 30 min in the dark followed by two washes as before, resuspended in 500 μl. For nuclear FOXP3 staining, cells were incubated with 1xFOXP3 buffer A for 10 min at room temperature; cells were washed as above and permeabilized with buffer C for 30 min at room temperature. The cells were washed as before, resuspended in stain buffer and incubated with anti- FOXP3 (APC, clone 259D/c7) and anti TGF-β (PE, clone TW4-9E7) at room temperature for 30 min in the dark followed by two washes as before and suspended in 500μl of staining buffer. To detect phosphorylation status of STAT3, cultured cells were first fixed for 10 min at room temperature, permeabilized as before with appropriate buffer and stained with a cocktail of PE labeled anti mouse pSTAT3, anti human IL-17A, CD3, CD4 and CCR6 antibodies. Stained cells were acquired by FACS aria (BD Biosciences, San Diego, CA) and analyzed by BD FACS Diva software.</p>
</sec>
<sec id="sec013">
<title>Estimation of cytokines by ELISA</title>
<p>Cytokines (IL-17A/F, IL-21, IL-22, IL-23A, IL-6, IL-1β, IFN-γ and TGF-β) were measured in duplicate by ELISA in culture supernatants from unstimulated and antigen stimulated PBMCs of leprosy patients (Ready Set Go, e-Bioscience, San Diego, CA, USA) as per manufacturer’s instructions. In brief, 96-well plates (Nunc, Rochester, NY, USA) were coated overnight at 4°C with biotin conjugated anti human antibodies for each of the cytokines, Plates were washed 5 times, blotted and wells blocked with assay diluents for 1 h at room temperature. 100ul/well of culture supernatant was added and plates incubated overnight at 4°C. After washing with buffer, avidin-horseradish peroxidase-conjugated anti-mouse antibody was added and the plates incubated at room temperature for 30 min. Subsequent to washing wells as before, color development was undertaken using TMB (Tetramethylbanzedine) substrate and the reaction stopped by 1 N H<sub>2</sub>SO<sub>4</sub>. The optical density (OD) of each well was read at 450 nm.</p>
</sec>
<sec id="sec014">
<title>Statistical analysis</title>
<p>Graph Pad Prism version 5 (GraphPad Software, Inc., San Diego, CA, USA) was used for two tailed Mann-Whitney for significance and Spearman nonparametric correlation coefficient. Student t test was used for fold change differences as per the manufacturer’s software. p&lt; 0.05 was considered as statistically significant. Heat map of gene expression were established by online software of SA bioscience (pcrdataanalysis.sabiosciences.com).</p>
</sec>
</sec>
<sec id="sec015" sec-type="results">
<title>Results</title>
<p><italic>Ex vivo</italic> antigen stimulated and unstimulated PBMC were investigated in patients with Type 1/reversal reaction (RR) and Type 2/ erythema nodosum leprosum (ENL) leprosy reactions prior to institution of anti reaction therapy with steroids, clofazamine or thalidomide. They were compared with complementary clinical groups of BT or LL respectively where the subjects were freshly diagnosed, untreated and without clinical evidence or previous history of reactions. Quantitative real time PCR (qPCR) was used for gene expression, flow cytometry for phenotypic characterization and intracellular cytokines and ELISA for measuring cytokines in culture supernatants. The demographic details of the 4 clinical groups of leprosy patients are given in <xref ref-type="table" rid="pntd.0004592.t001">Table 1</xref>.</p>
<sec id="sec016">
<title>Th17 cell increase in leprosy reactions</title>
<sec id="sec017">
<title>qPCR</title>
<p><xref ref-type="fig" rid="pntd.0004592.g001">Fig 1</xref> shows a significant increase in fold changes in RR group as compared to stable BT patients for all IL-17 isomers in MLSA stimulated PBMC (IL-17A p&lt; 0.0001, IL-17F p&lt;0.003, IL-17C p&lt;0.001, IL-17D p&lt;0.01; the respective fold change was 13.6, 13.7, 7.0 and 14.2. ENL patients also showed significant but relatively higher increase in fold changes ranging from 7.6 to 19.7 (p&lt;0.02–0.001) as compared to stable LL group (<xref ref-type="fig" rid="pntd.0004592.g001">Fig 1b</xref>). Of interest was the greater fold change in IL-17A as compared to other IL-17 isomers. The increased fold change seen in ENL as compared to RR is mainly due to the low baseline levels noted in the anergic LL background type of leprosy (<xref ref-type="table" rid="pntd.0004592.t002">Table 2</xref>). RORC the molecular signature of Th17 cells also showed fold increase in both reactions (p&lt;0.001) with relatively higher fold change in RR (8.8) as compared to ENL (6.4). The above features were further confirmed by ELISA in PBMC culture supernatants of leprosy patients with and without reactions (<xref ref-type="table" rid="pntd.0004592.t003">Table 3</xref>). There was significantly higher (p&lt;0.0001) levels of IL-17A/F in RR and ENL patients as compared respectively to non reactive BT and LL. Stable LL patients showed the lowest levels of cytokines as compared to other clinical types as reported earlier [<xref ref-type="bibr" rid="pntd.0004592.ref027">27</xref>].</p>
<fig id="pntd.0004592.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0004592.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Fold change in gene expression of Th17, Treg, Th1 and 2 associated markers in leprosy reaction patients (RR,ENL) as compared to matching stable leprosy patients (BT, LL) as evaluated by qPCR of <italic>ex-vivo</italic> antigen (MLSA) stimulated PBMC.</title>
<p>Horizontal histogram shows significant fold increase in (a) RR, (b) ENL as compared to BT, LL patients respectively for gene expression of Th17 and Treg associated cytokines, receptors and transcription factors as well as Th1 and Th2 cytokines. p value was calculated based on a Student’s t-test and p&lt; 0.05 was considered to be statistically significant. Abbreviations: BT; borderline tuberculoid, RR; reversal reaction, LL; lepromatous leprosy, ENL; erythema nodosum leprosum as per Ridley Jopling classification[<xref ref-type="bibr" rid="pntd.0004592.ref002">2</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref029">29</xref>], ns = non significant.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0004592.g001" xlink:type="simple"/>
</fig>
<table-wrap id="pntd.0004592.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0004592.t002</object-id>
<label>Table 2</label> <caption><title>Mean ΔCt ±SD of cytokines, signaling molecules, and transcription factors of 48 hr. MLSA stimulated PBMC from stable (BT, LL) and reactions (RR, ENL) leprosy patients.</title></caption>
<alternatives>
<graphic id="pntd.0004592.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0004592.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left"/>
<th align="left" colspan="4">ΔCt (Mean±SD)</th>
<th align="left" colspan="3">P value</th>
</tr>
<tr>
<th align="left">Gene</th>
<th align="left">BT</th>
<th align="left">LL</th>
<th align="left">ENL</th>
<th align="left">RR</th>
<th align="left">BT vs RR</th>
<th align="left">LL vs ENL</th>
<th align="left">RR vs ENL</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><bold>IL-17A</bold></td>
<td align="left">6.6±2.5</td>
<td align="left">12.9±2.4</td>
<td align="left">5.5±3.3</td>
<td align="left">4.1±0.6</td>
<td align="left">0.0003</td>
<td align="left">0.002</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left"><bold>IL-17C</bold></td>
<td align="left">6.1±1.5</td>
<td align="left">9.1±2.0</td>
<td align="left">5.3±2.6</td>
<td align="left">4.5±0.7</td>
<td align="left">0.006</td>
<td align="left">0.005</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left"><bold>IL-17D</bold></td>
<td align="left">8.6±0.5</td>
<td align="left">11.9±1.6</td>
<td align="left">7.8±3.1</td>
<td align="left">6.5±0.8</td>
<td align="left">0.0002</td>
<td align="left">0.01</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left"><bold>IL-17F</bold></td>
<td align="left">5.2±0.4</td>
<td align="left">9.6±2.3</td>
<td align="left">4.3±1.9</td>
<td align="left">3.8±0.8</td>
<td align="left">0.001</td>
<td align="left">0.001</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left"><bold>IL-22</bold></td>
<td align="left">5.4±2.2</td>
<td align="left">10.0±2.8</td>
<td align="left">4.6±3.3</td>
<td align="left">2.9±0.5</td>
<td align="left">0.0003</td>
<td align="left">0.004</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left"><bold>TNF-α</bold></td>
<td align="left">4.3±0.8</td>
<td align="left">4.7±0.8</td>
<td align="left">5.1±1.3</td>
<td align="left">4.0±0.9</td>
<td align="left">ns</td>
<td align="left">ns</td>
<td align="left">0.01</td>
</tr>
<tr>
<td align="left"><bold>IL-6R</bold></td>
<td align="left">3.7±0.6</td>
<td align="left">3.1±0.6</td>
<td align="left">3.5±0.7</td>
<td align="left">3.2±1.4</td>
<td align="left">ns</td>
<td align="left">ns</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left"><bold>IL23R</bold></td>
<td align="left">5.0±0.8</td>
<td align="left">10.2±3.2</td>
<td align="left">4.7±3.6</td>
<td align="left">3.5±0.8</td>
<td align="left">0.004</td>
<td align="left">0.006</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left"><bold>STAT3</bold></td>
<td align="left">2.9±0.7</td>
<td align="left">3.0±0.3</td>
<td align="left">2.2±0.9</td>
<td align="left">2.5±0.6</td>
<td align="left">ns</td>
<td align="left">ns</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left"><bold>FOXP3</bold></td>
<td align="left">7.2±1.8</td>
<td align="left">5.0±1.6</td>
<td align="left">5.5±1.7</td>
<td align="left">4.8±0.8</td>
<td align="left">0.001</td>
<td align="left">ns</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left"><bold>RORC</bold></td>
<td align="left">5.2±0.5</td>
<td align="left">8.8±0.8</td>
<td align="left">5.0±2.6</td>
<td align="left">3.5±0.8</td>
<td align="left">0.001</td>
<td align="left">0.004</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left"><bold>IL-23A</bold></td>
<td align="left">4.6±0.7</td>
<td align="left">7.2±1.0</td>
<td align="left">3.8±2.0</td>
<td align="left">3.1±0.5</td>
<td align="left">0.0004</td>
<td align="left">0.004</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left"><bold>IL-1β</bold></td>
<td align="left">2.3±1.3</td>
<td align="left">3.1±1.3</td>
<td align="left">3.0±1.3</td>
<td align="left">1.9±1.0</td>
<td align="left">ns</td>
<td align="left">ns</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left"><bold>TGF-β</bold></td>
<td align="left">3.2±0.5</td>
<td align="left">2.4±0.7</td>
<td align="left">3.0±1.0</td>
<td align="left">2.7±1.1</td>
<td align="left">ns</td>
<td align="left">ns</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left"><bold>IL-6</bold></td>
<td align="left">5.0±0.8</td>
<td align="left">7.3±2.8</td>
<td align="left">4.4±2.0</td>
<td align="left">3.6±0.6</td>
<td align="left">0.001</td>
<td align="left">0.04</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left"><bold>IL-21</bold></td>
<td align="left">4.7±0.5</td>
<td align="left">9.0±2.3</td>
<td align="left">5.3±3.5</td>
<td align="left">3.3±0.7</td>
<td align="left">0.002</td>
<td align="left">0.03</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left"><bold>CCL20</bold></td>
<td align="left">5.5±1.5</td>
<td align="left">6.6±2.4</td>
<td align="left">4.0±1.8</td>
<td align="left">3.3±0.7</td>
<td align="left">0.001</td>
<td align="left">0.02</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left"><bold>CCL22</bold></td>
<td align="left">4.2±1.2</td>
<td align="left">5.0±1.2</td>
<td align="left">3.6±0.9</td>
<td align="left">3.2±0.9</td>
<td align="left">ns</td>
<td align="left">0.02</td>
<td align="left">ns</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p>Classification of patients according to Ridley Jopling[<xref ref-type="bibr" rid="pntd.0004592.ref002">2</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref029">29</xref>] as in legend to <xref ref-type="table" rid="pntd.0004592.t001">Table 1</xref>. Peripheral blood mononuclear cells (PBMC) *p&lt; 0.01, ** p&lt; 0.001, *** p&lt; 0.0001 by two tailed Mann Whitney test. P&lt;0.05 was considered significant, ns = non significant</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="pntd.0004592.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0004592.t003</object-id>
<label>Table 3</label> <caption><title>Mean pg/ml ± SD of cytokines in culture supernatants of 48 hr.</title> <p><italic>M</italic>.<italic>leprae</italic> stimulated PBMC from 10 each of stable tuberculoid (BT), reversal reaction (RR) stable lepromatous leprosy (LL) and erythema leprosum reaction (ENL) patients investigated for gene expression study.</p></caption>
<alternatives>
<graphic id="pntd.0004592.t003g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0004592.t003" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Cytokine</th>
<th align="center">BT</th>
<th align="center">RR</th>
<th align="center">LL</th>
<th align="center">ENL</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">IL-17A</td>
<td align="left">101.9±2.6</td>
<td align="left">219.8±28.07<xref ref-type="table-fn" rid="t003fn004">***</xref></td>
<td align="left">45.52±22.7</td>
<td align="left">650±195.2<xref ref-type="table-fn" rid="t003fn004">***</xref></td>
</tr>
<tr>
<td align="left">IL-21</td>
<td align="left">314±19.1</td>
<td align="left">346±30.4<xref ref-type="table-fn" rid="t003fn002">*</xref></td>
<td align="left">267.4±11.5</td>
<td align="left">232.5±48.5</td>
</tr>
<tr>
<td align="left">IL-22</td>
<td align="left">561±118</td>
<td align="left">492.8±115.0</td>
<td align="left">633.1±89.1<xref ref-type="table-fn" rid="t003fn004">***</xref></td>
<td align="left">96.72±93.0</td>
</tr>
<tr>
<td align="left">IL-23A</td>
<td align="left">62.6±51.2</td>
<td align="left">131.9±45.9<xref ref-type="table-fn" rid="t003fn003">**</xref></td>
<td align="left">23.64±10.4</td>
<td align="left">48.51±45.2<xref ref-type="table-fn" rid="t003fn002">*</xref></td>
</tr>
<tr>
<td align="left">IL-1β</td>
<td align="left">13.6±16.3</td>
<td align="left">7.3±1.1</td>
<td align="left">8.5±4.4</td>
<td align="left">22.4±12.2<xref ref-type="table-fn" rid="t003fn003">**</xref></td>
</tr>
<tr>
<td align="left">IL-6</td>
<td align="left">50.5±27.9</td>
<td align="left">122±21.6<xref ref-type="table-fn" rid="t003fn004">***</xref></td>
<td align="left">21.8±10.9</td>
<td align="left">439.1±203.0<xref ref-type="table-fn" rid="t003fn003">**</xref></td>
</tr>
<tr>
<td align="left">TGF-β</td>
<td align="left">104.4±45.7</td>
<td align="left">80.5±13.0</td>
<td align="left">312±98.1</td>
<td align="left">297.5±65.8</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001"><p>Classification according to Ridley Jopling classification [<xref ref-type="bibr" rid="pntd.0004592.ref002">2</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref029">29</xref>]. Legend as in <xref ref-type="table" rid="pntd.0004592.t002">Table 2</xref></p></fn>
<fn id="t003fn002"><p>*p&lt; 0.01</p></fn>
<fn id="t003fn003"><p>** p&lt; 0.001</p></fn>
<fn id="t003fn004"><p>*** p&lt; 0.0001 by two tailed Mann Whitney test. P&lt;0.05 was considered significant.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec018">
<title>Flowcytometry</title>
<p>Further validation of the above data was obtained with flow cytometric analysis to identify the T cell phenotype in 48 h MLSA stimulated PBMC cultures. As expected (<xref ref-type="fig" rid="pntd.0004592.g002">Fig 2</xref>), the intracellular presence of IL-17A, F and IL-21 was associated with CD3<sup>+</sup>CD4<sup>+</sup> cells in all the clinical groups. Reversal reaction (RR) patients showed significantly higher (p&lt;0.001) percentages of CD3 gated CD4<sup>+</sup>IL-17A<sup>+</sup> and CD4<sup>+</sup>IL-17F<sup>+</sup> cells as compared to non-reactive BT subjects (<xref ref-type="fig" rid="pntd.0004592.g002">Fig 2A and 2B</xref>). However, there was no difference in the percentage of IL-21<sup>+</sup>cells in RR and stable BT groups (<xref ref-type="fig" rid="pntd.0004592.g002">Fig 2C</xref>).</p>
<fig id="pntd.0004592.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0004592.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Increase in IL-17 and IL-21 bearing CD3<sup>+</sup>CD4<sup>+</sup> T cells in patients undergoing leprosy reactions.</title>
<p>Flowcytometry analysis of antigen stimulated PBMC from one each of representative patient with RR, BT, ENL, and LL leprosy (see <xref ref-type="sec" rid="sec005">Materials and Methods</xref>). Dot plot shows percentage of CD3<sup>+</sup> gated CD4<sup>+</sup> cells with intracellular IL-17A (Figs A, D), IL-17F (Figs B, E) and IL-21 (Figs C, F) in BT, RR and LL, ENL subjects. Scattergram (Mean % ± SD of cells) confirms the significant increase in percentage of Th17 cells in RR, ENL compared to BT, LL patients respectively for IL-17A, IL-17F cytokines as indicated by p values. IL-21<sup>+</sup> cells were increased only in ENL. p&lt; 0.05 was considered statistically significant (two tailed Mann-Whitney). (), parenthesis shows number of subjects tested. Abbreviations as in <xref ref-type="fig" rid="pntd.0004592.g001">Fig 1</xref>.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0004592.g002" xlink:type="simple"/>
</fig>
<p>ENL patients (<xref ref-type="fig" rid="pntd.0004592.g002">Fig 2</xref>) also showed significant (p&lt;0.001) increases in the percentages of IL-17A<sup>+</sup> (<xref ref-type="fig" rid="pntd.0004592.g002">Fig 2D</xref>), IL-17F<sup>+</sup> (<xref ref-type="fig" rid="pntd.0004592.g002">Fig 2E</xref>) cells similar to patients with reversal reactions. Unlike RR patients with ENL showed an increase in IL-21<sup>+</sup> cells (<xref ref-type="fig" rid="pntd.0004592.g002">Fig 2F</xref>) as compared to stable non- reactive LL patients. In conclusion, Th17 cells with intracellular IL-17A, F are increased in both types of leprosy reactions whereas CD4<sup>+</sup>IL-21<sup>+</sup> cells were higher only in ENL reactions patients.</p>
</sec>
</sec>
<sec id="sec019">
<title>Other Th17 associated cytokines, receptors and chemokines in <italic>ex vivo</italic> 48hr PBMC cultures</title>
<p>Cytokines IL-1β, IL-23 which have been reported to influence and sustain Th17 lineage [<xref ref-type="bibr" rid="pntd.0004592.ref030">30</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref031">31</xref>] were investigated (<xref ref-type="fig" rid="pntd.0004592.g001">Fig 1</xref>). In general, the expression of IL-23A was significantly up regulated in <italic>ex vivo</italic> antigen stimulated PBMC of reactions patients compared to non reactive patients reflecting differences due to recall responses in antigen stimulated PBMC as compared to the status of an ongoing <italic>in vivo</italic> response. Fold change of IL-23Aexpression was significantly up regulated in both RR(p&lt;0.001) and ENL(p&lt;0.02,) as compared to BT and LL patients respectively. Moreover, cytokine levels in <italic>ex-vivo</italic> cultures by ELISA supported data obtained with qPCR. (<xref ref-type="table" rid="pntd.0004592.t003">Table 3</xref>)</p>
<p>IL-23R expression also showed significant fold change/increase in RR and ENL, with the latter showing a higher increase in RR (p&lt;0.001) as compared to ENL (p&lt;0.01). Expression of IL-23R also correlated with their expression of respective ligands (IL-23A) as indicated by Spearman r correlation of (r<sup>2</sup> = 0.92, p&lt;0.0001 and r<sup>2</sup> = 0.71, p&lt;0.0001) respectively indicative of their functional relevance. IL-1β expression did not show any difference in RR and BT patients (<xref ref-type="fig" rid="pntd.0004592.g001">Fig 1</xref> and <xref ref-type="table" rid="pntd.0004592.t003">Table 3</xref>). However, at protein level IL-1β showed a preferential increase in ENL by ELISA indicating that 48h culture period may have missed the time kinetics of gene expression whereas supernatants reflected the accumulation of the translated product.</p>
<p>Since leprosy reactions are inflammatory in nature we also looked at the role of common chemokines and cytokines. As shown in <xref ref-type="table" rid="pntd.0004592.t002">Table 2</xref>, expression of CCL20, and CCL22 were seen to be highest in antigen stimulated PBMC cultures of RR and ENL as compared to stable disease. Both of these chemokines showed significant increases in fold changes in RR and ENL (p&lt;0.001, p&lt;0.02) as compared to BT and LL respectively. CCL22 showed increased fold change only in ENL (p&lt;0.02) and not in RR patients. Cytokines associated with Th1 and Th2 subsets showed fold change increases in both reactions. Whereas RR showed increase in both Th1[<xref ref-type="bibr" rid="pntd.0004592.ref032">32</xref>] and Th2 cytokines, ENL showed significant fold change increase only in IFN-γ as reported earlier[<xref ref-type="bibr" rid="pntd.0004592.ref008">8</xref>].</p>
</sec>
<sec id="sec020">
<title>CCR6<sup>+</sup>Th17 cell increase in leprosy reactions</title>
<p>We next investigated the expression of CD4<sup>+</sup>IL-17<sup>+</sup> cells with CCR6, an effector /memory T cell marker [<xref ref-type="bibr" rid="pntd.0004592.ref033">33</xref>] using flow cytometry. During both RR (<xref ref-type="fig" rid="pntd.0004592.g003">Fig 3A</xref>) and ENL (<xref ref-type="fig" rid="pntd.0004592.g003">Fig 3E</xref>) reaction states, patients showed significant (p&lt;0.02, p&lt;0.03) up regulation of the CD4<sup>+</sup>CCR6<sup>+</sup> population as compared to the respective stable forms. Moreover, this subset of cells produced IL-17. As reported earlier[<xref ref-type="bibr" rid="pntd.0004592.ref027">27</xref>], the present study also confirmed that CD4<sup>+</sup>IL-17<sup>+</sup>CCR6<sup>+</sup> effector T cells were significantly (p&lt;0.03) higher in stable BT than LL patients (<xref ref-type="fig" rid="pntd.0004592.g003">Fig 3B and 3F</xref>). However, as noted above, the two reactions showed differences in subtypes of IL-17<sup>+</sup> as well as IL-21<sup>+</sup> cells. Both reaction types showed increase in the percentage of IL-17A<sup>+</sup> cells (<xref ref-type="fig" rid="pntd.0004592.g003">Fig 3B and 3F</xref>). Significantly higher IL-17A<sup>+</sup> (p&lt;0.03) but not IL-17F<sup>+</sup> producing CCR6<sup>+</sup>Th17<sup>+</sup> cells were seen in RR (<xref ref-type="fig" rid="pntd.0004592.g003">Fig 3C</xref>) as compared to the non reactive counterpart. In ENL reactions however, both IL-17A<sup>+</sup> and IL-17F<sup>+</sup> cells showed increases as compared to stable LL (<xref ref-type="fig" rid="pntd.0004592.g003">Fig 3F and 3G</xref> respectively). It is of interest that IL-21<sup>+</sup>effector cell populations was increased in RR as compared to BT patients (<xref ref-type="fig" rid="pntd.0004592.g003">Fig 3D</xref>, p&lt;0.01) whereas no differences were noted between ENL and LL patients (<xref ref-type="fig" rid="pntd.0004592.g003">Fig 3H</xref>).</p>
<fig id="pntd.0004592.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0004592.g003</object-id>
<label>Fig 3</label>
<caption>
<title>CD4+CCR6+ effector Th17 cells are increased in patients undergoing leprosy reactions.</title>
<p>Flowcytometry analysis of antigen stimulated PBMC from one representative patient of RR, BT, ENL and LL (see <xref ref-type="sec" rid="sec005">Materials and Methods</xref>). Fig 3 and e show dot blots with increase in percentage of CD3<sup>+</sup> CD4<sup>+</sup>CCR6<sup>+</sup> cells in RR as compared to BT (A) and ENL as compared to LL patient(E). Histograms show increase in percentages of intracellular IL-17A<sup>+</sup> (B, F), IL-17F<sup>+</sup> (C, G) and IL-21<sup>+</sup> cells (D, H) in both leprosy reactions as compared to stable leprosy patients. Scattergrams show individual data with Mean % ± SD of IL-17A/F, IL-21 in patient groups. p&lt; 0.05 was considered statistically significant (two tailed Mann-Whitney). (), Parenthesis shows number of subjects tested. Abbreviations as in <xref ref-type="fig" rid="pntd.0004592.g001">Fig 1</xref>.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0004592.g003" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec021">
<title>p-STAT3<sup>+</sup> IL-17 <sup>+</sup>cells in leprosy reactions</title>
<p>STAT3 expression by qPCR showed low / non significant increase in RR and ENL as compared to their respective stable forms of BT and LL groups in the antigen stimulated PBMC cultures (<xref ref-type="fig" rid="pntd.0004592.g001">Fig 1</xref>). We further investigated the requirement for phosphorylation of STAT3 in CCR6<sup>+</sup> IL-17A<sup>+</sup> cells using flowcytometry in 3 of each leprosy patients. <xref ref-type="fig" rid="pntd.0004592.g004">Fig 4A</xref> shows higher percentage of pSTAT3<sup>+</sup>IL-17<sup>+</sup> cells in patients undergoing leprosy reactions as compared to non reaction patients. Moreover, co-expression of STAT3 and IL-17 isomers as indicated by qPCR also showed significant correlation (<xref ref-type="fig" rid="pntd.0004592.g004">Fig 4B</xref>). (IL-17A; r<sup>2</sup> = 0.059, p&lt;0.01, IL-17D; r<sup>2</sup> = 0.07, p&lt;0.01, IL-17C; r<sup>2</sup> = 0.093, p&lt;0.001, IL-17F; r<sup>2</sup> = 0.077, p&lt;0.01)</p>
<fig id="pntd.0004592.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0004592.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Increase in pSTAT3+IL17+ cells in leprosy reactions patients.</title>
<p>Flow cytometry analysis of antigen stimulated 48 h culture of PBMC shows increase in pSTAT3 bearing CCR6<sup>+</sup> cells with intracellular IL-17A in both RR and ENL subjects as compared to matching stable leprosy (a) Representative dot plots from each of RR, BT and ENL, LL leprosy patients (see <xref ref-type="sec" rid="sec005">Materials and Methods</xref>). (b) Scatter plots of combined qPCR data from both reaction patients RR and ENL, showing significant positive correlation of <italic>STAT3</italic> expression (ΔCT) with <italic>IL17A</italic>, <italic>IL17D</italic>, <italic>IL17C</italic> and <italic>IL17F</italic>. Correlation coefficient (r<sup>2</sup>) was calculated by Spearman non-parametric correlation test, p&lt; 0.05 was considered statistically significant. p&lt;0.01 = *, p&lt;0.001 = **, Abbreviations as in <xref ref-type="fig" rid="pntd.0004592.g001">Fig 1</xref>.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0004592.g004" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec022">
<title>CD4<sup>+</sup>CD25<sup>+</sup> FOXP3<sup>+</sup> T cells</title>
<p>The role of FOXP3<sup>+</sup> regulatory T cells (Treg) during leprosy reactions was investigated using both qPCR and flow cytometry analysis of <italic>ex vivo</italic> stimulated PBMC from both stable and matching leprosy reaction groups (Figs <xref ref-type="fig" rid="pntd.0004592.g001">1</xref>, <xref ref-type="fig" rid="pntd.0004592.g005">5a and 5b</xref>). In confirmation of our earlier studies [<xref ref-type="bibr" rid="pntd.0004592.ref025">25</xref>], Tregs were increased in LL as compared to BT and produced TGF-β. RR and ENL patients however showed a decrease in Treg cells (p&lt;0.02 to p&lt;0.003) as compared to the nonreactive disease (<xref ref-type="fig" rid="pntd.0004592.g005">Fig 5c and 5d</xref>). This was further confirmed by qPCR studies (<xref ref-type="fig" rid="pntd.0004592.g001">Fig 1</xref>), where 5.5 fold increase in FOXP3 gene expression (p&lt;0.001) was observed in stimulated PBMC from the RR and ENL group (p&lt;0.008) as compared to patients with stable disease.</p>
<fig id="pntd.0004592.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0004592.g005</object-id>
<label>Fig 5</label>
<caption>
<title>Reduction of FOXP3 and TGF-β in T cells of leprosy reaction patients.</title>
<p>Flowcytometry analysis demonstrates reduction in percentage of CD3<sup>+</sup>CD4<sup>+</sup>gated CD25<sup>+</sup>FOXP3<sup>+</sup> cells (see <xref ref-type="sec" rid="sec005">Materials and Methods</xref>). Dot plots show percentage of CD25<sup>+</sup>FOXP3<sup>+</sup> cells in representative patients with RR, ENL as compared to stable BT, LL patients respectively. Histogram shows MFI (mean florescent intensity) of nuclear FOXP3 and intracellular TGF-β in each of RR and ENL as compared to respective BT and LL (Figs a, b). Bar diagram shows MFI of nuclear FOXP3 and TGF-β (mean±SD) in RR, ENL as compared to BT, LL leprosy groups respectively (Figs b, c). Data were analyzed using two tailed Mann-Whitney, p&lt; 0.05 was considered as statistically significant. (), Parenthesis shows number of subjects tested. Abbreviations as <xref ref-type="fig" rid="pntd.0004592.g001">Fig 1</xref>.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0004592.g005" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec023">
<title>Role of TGF-β and IL 6</title>
<p>We investigated levels of the inhibitory cytokine TGF-β using flow cytometry. Intracellular TGF-β was evaluated in CD4+CD25+FOXP3+Treg cells (<xref ref-type="fig" rid="pntd.0004592.g005">Fig 5a and 5b</xref>). MFI (mean florescence intensity) showed significant (p&lt;0.02) down regulation of TGF-β (<xref ref-type="fig" rid="pntd.0004592.g005">Fig 5c</xref>) in patients showing both reactions states. RR patients showed significantly reduced MFI for TGF-β (p&lt;0.02) as compared to BT as did ENL patients in comparison to stable LL patients (p&lt;0.001, <xref ref-type="fig" rid="pntd.0004592.g005">Fig 5d</xref>). However TGF-β expression by qPCR showed no change in RR and ENL as compared to the matching stable leprosy groups (<xref ref-type="fig" rid="pntd.0004592.g001">Fig 1</xref> and <xref ref-type="table" rid="pntd.0004592.t003">Table 3</xref>) which may be related to the difference in time kinetics in the PBMC cultures for expression of the genes as compared to the intracellular cytokine production.</p>
<p>Recent reports [<xref ref-type="bibr" rid="pntd.0004592.ref021">21</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref023">23</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref024">24</xref>] support the idea that Th17 differentiation is controlled by the opposing roles of TGF-β and IL-6. In contrast, we found that TGF-β, IL-6 expression by qPCR showed up-regulation during both reactions (p&lt;0.01–0.005) as compared to the stable forms (<xref ref-type="fig" rid="pntd.0004592.g001">Fig 1</xref>). We then investigated the nature of cells producing IL-6 in four patients of each leprosy group. Lymphocyte populations did not show any evidence of intracellular IL-6 (<xref ref-type="fig" rid="pntd.0004592.g006">Fig 6a</xref>). Instead, flow analysis indicated that the cell populations gated for monocytes and granulocytes predominated. (<xref ref-type="fig" rid="pntd.0004592.g006">Fig 6b and 6c</xref>). Both types of leprosy reactions showed increases in percentages of IL-6<sup>+</sup> monocytes (p&lt;0.02) as compared to stable leprosy, whereas the IL-6<sup>+</sup> granulocyte population showed no differences in the reactive and non reactive groups (<xref ref-type="table" rid="pntd.0004592.t004">Table 4</xref>).</p>
<fig id="pntd.0004592.g006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0004592.g006</object-id>
<label>Fig 6</label>
<caption>
<title>IL-6 increase in leprosy reactions is associated with monocyte population in antigen stimulated PBMC cultures of patients.</title>
<p>Fig 6(a) shows monocytes gating strategy in flowcytometry. Histogram represents percentage of IL-6<sup>+</sup> population in monocyte and lymphocyte populations in one each of (b, d) RR, BT and (c,e) ENL, LL respectively. Scattergrams shows pooled qPCR data where <italic>TGF-β</italic> and <italic>IL-6</italic> gene expression was undertaken on antigen stimulated PBMC of patients of (f) non-reaction stable (BT, LL) and (g) leprosy reaction (RR, ENL) patients. Correlation coefficient (r<sup>2</sup>) was calculated by Spearman nonparametric correlation test, p&lt; 0.05 was considered statistically significant. Abbreviations as in <xref ref-type="fig" rid="pntd.0004592.g001">Fig 1</xref>.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0004592.g006" xlink:type="simple"/>
</fig>
<table-wrap id="pntd.0004592.t004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0004592.t004</object-id>
<label>Table 4</label> <caption><title>Mean percentage ± SD of IL-6<sup>+</sup> cells in gated populations of monocytes, granulocytes and lymphocytes in antigen stimulated PBMC of four patients each of stable tuberculoid (BT), lepromatous (LL) and corresponding leprosy reactions RR and ENL respectively studied by flowcytometry as depicted in <xref ref-type="fig" rid="pntd.0004592.g006">Fig 6</xref>.</title></caption>
<alternatives>
<graphic id="pntd.0004592.t004g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0004592.t004" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Gated cell populations</th>
<th align="center" colspan="4">IL-6<sup>+</sup> cells (Mean % ± SD) in patient groups</th>
</tr>
<tr>
<th align="left"/>
<th align="center">RR</th>
<th align="center">BT</th>
<th align="center">ENL</th>
<th align="center">LL</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Monocytes</td>
<td align="center">8.6±1.0<xref ref-type="table-fn" rid="t004fn001">*</xref></td>
<td align="center">4.4±0.6</td>
<td align="center">18.8±0.6<xref ref-type="table-fn" rid="t004fn001">*</xref></td>
<td align="center">4.1±0.2</td>
</tr>
<tr>
<td align="left">Granulocytes</td>
<td align="center">23.5±6.6</td>
<td align="center">17.4±0.8</td>
<td align="center">15.5±0.8</td>
<td align="center">15.6±0.5</td>
</tr>
<tr>
<td align="left">Lymphocytes</td>
<td align="center">1.7±0.3</td>
<td align="center">1.1±0.3</td>
<td align="center">1.6±0.4</td>
<td align="center">0.7±0.4</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t004fn001"><p>*p&lt; 0.04, by two tailed Mann Whitney test. P&lt;0.05 was considered significant.</p></fn>
<fn id="t004fn002"><p>Patient classification and abbreviations as in <xref ref-type="table" rid="pntd.0004592.t001">Table 1</xref></p></fn>
</table-wrap-foot>
</table-wrap>
<p>The opposing role of these two cytokines were analyzed using Spearman correlation coefficient by pooling data obtained in qPCR studies from the reaction groups as compared to non-reactive groups (<xref ref-type="fig" rid="pntd.0004592.g006">Fig 6f and 6g</xref>). TGF-β and IL-6 revealed opposing effects with negative correlation (r<sup>2</sup> = -0.45, p&lt;0.04) in stable leprosy and a positive correlation in leprosy reactions (r<sup>2</sup> = 0.49, p&lt;0.02).</p>
</sec>
<sec id="sec024">
<title>Differential expression of genes in reversal and ENL reactions</title>
<p>With a view to understanding the differences between the immunopathology/inflammation associated with the localized reversal and generalized ENL forms of reactions we analyzed the expression of 84 genes in qPCR assay (<xref ref-type="fig" rid="pntd.0004592.g007">Fig 7</xref> and <xref ref-type="table" rid="pntd.0004592.t005">Table 5</xref>). Heat map of gene expression as reported earlier [<xref ref-type="bibr" rid="pntd.0004592.ref027">27</xref>], shows that stable BT subjects had higher expression of many genes as compared to anergic LL. Further increase in expression was observed in reaction subjects. Although there was individual variability, in general, RR subjects showed higher expression of genes expressing cell surface markers, cytokines, cytokine receptors, chemokines, signaling molecules and transcription factors as compared to ENL/Type 2 reactions. <xref ref-type="table" rid="pntd.0004592.t005">Table 5</xref> provides data on the stastical significance of the fold changes in gene expression in patients with these two reaction types</p>
<fig id="pntd.0004592.g007" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0004592.g007</object-id>
<label>Fig 7</label>
<caption>
<title>Heat map of customized PCR array showing differential expression of 84 genes in antigen stimulated PBMC of leprosy groups.</title>
<p><bold>E</bold>ach horizontal row represents the same gene product and each vertical row the same patient. The fluorescence range from high (red) to low (green) is indicated by the colored bar and reflects the degree of fluorescence intensity/gene expression. Heat map obtained from online free software S.A Bioscience (pcrdataanalysis.sabiosciences.com). In general, PBMC of patients in reactions show higher expression of several genes representing, cytokines, cytokine receptors, cheekiness and transcription factors as compared to non reaction patients (see also <xref ref-type="table" rid="pntd.0004592.t005">Table 5</xref>). Abbreviations as in <xref ref-type="fig" rid="pntd.0004592.g001">Fig 1</xref>.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0004592.g007" xlink:type="simple"/>
</fig>
<table-wrap id="pntd.0004592.t005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0004592.t005</object-id>
<label>Table 5</label> <caption><title>Expression of surface molecules, cytokines, signaling molecules, chemokines, receptors and transcription factors evaluated by qPCR where fold change between stable and reaction groups showed significant differences in RR and ENL.</title></caption>
<alternatives>
<graphic id="pntd.0004592.t005g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0004592.t005" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left"/>
<th align="left">RR</th>
<th align="left">ENL</th>
<th align="left"/>
<th align="left">RR</th>
<th align="left">ENL</th>
<th align="left"/>
<th align="left">RR</th>
<th align="left">ENL</th>
</tr>
<tr>
<th align="left" colspan="3">Surface Molecules</th>
<th align="left" colspan="3">Cytokines</th>
<th align="left" colspan="3">Signaling Molecules, Transcriptional Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">CD247</td>
<td align="left">ns</td>
<td align="left">ns</td>
<td align="left">CSF2</td>
<td align="left">0.001</td>
<td align="left">0.02</td>
<td align="left">CEBPB</td>
<td align="left">ns</td>
<td align="left">0.03</td>
</tr>
<tr>
<td align="left">CD28</td>
<td align="left">0.0001</td>
<td align="left">0.03</td>
<td align="left">CSF3</td>
<td align="left">0.001</td>
<td align="left">0.02</td>
<td align="left">CLEC7A</td>
<td align="left">0.0001</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left">CD34</td>
<td align="left">0.0001</td>
<td align="left">ns</td>
<td align="left">IFN-γ</td>
<td align="left">0.001</td>
<td align="left">0.05</td>
<td align="left">S1PR1</td>
<td align="left">ns</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left">CD3D</td>
<td align="left">ns</td>
<td align="left">ns</td>
<td align="left">IL10</td>
<td align="left">0.001</td>
<td align="left">ns</td>
<td align="left">FOXP3</td>
<td align="left">0.001</td>
<td align="left">0.03</td>
</tr>
<tr>
<td align="left">CD3E</td>
<td align="left">ns</td>
<td align="left">0.01</td>
<td align="left">IL12B</td>
<td align="left">0.0001</td>
<td align="left">ns</td>
<td align="left">GATA3</td>
<td align="left">0.0002</td>
<td align="left">0.04</td>
</tr>
<tr>
<td align="left">CD3G</td>
<td align="left">ns</td>
<td align="left">0.02</td>
<td align="left">IL13</td>
<td align="left">0.001</td>
<td align="left">ns</td>
<td align="left">JAK1</td>
<td align="left">0.02</td>
<td align="left">0.03</td>
</tr>
<tr>
<td align="left">CD4</td>
<td align="left">0.01</td>
<td align="left">ns</td>
<td align="left">IL15</td>
<td align="left">0.001</td>
<td align="left">ns</td>
<td align="left">JAK2</td>
<td align="left">0.01</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left">CD40LG</td>
<td align="left">0.001</td>
<td align="left">0.006</td>
<td align="left">IL17A</td>
<td align="left">0.0001</td>
<td align="left">0.002</td>
<td align="left">MMP13</td>
<td align="left">0.001</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left">CD8A</td>
<td align="left">0.001</td>
<td align="left">ns</td>
<td align="left">IL17C</td>
<td align="left">0.001</td>
<td align="left">0.005</td>
<td align="left">MMP3</td>
<td align="left">0.0003</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left">ICAM1</td>
<td align="left">ns</td>
<td align="left">ns</td>
<td align="left">IL17D</td>
<td align="left">0.001</td>
<td align="left">0.04</td>
<td align="left">MMP9</td>
<td align="left">ns</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left">ICOS</td>
<td align="left">0.0001</td>
<td align="left">0.04</td>
<td align="left">IL17F</td>
<td align="left">0.001</td>
<td align="left">0.001</td>
<td align="left">NFATC2</td>
<td align="left">0.005</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left">ISG20</td>
<td align="left">ns</td>
<td align="left">ns</td>
<td align="left">IL18</td>
<td align="left">0.002</td>
<td align="left">ns</td>
<td align="left">NFKB1</td>
<td align="left">ns</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left" colspan="3">Chemokines</td>
<td align="left">IL1β</td>
<td align="left">ns</td>
<td align="left">ns</td>
<td align="left">RORC</td>
<td align="left">0.0001</td>
<td align="left">0.02</td>
</tr>
<tr>
<td align="left">CCL1</td>
<td align="left">0.0001</td>
<td align="left">ns</td>
<td align="left">IL2</td>
<td align="left">0.0001</td>
<td align="left">ns</td>
<td align="left">SOCS1</td>
<td align="left">ns</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left">CCL2</td>
<td align="left">ns</td>
<td align="left">ns</td>
<td align="left">IL21</td>
<td align="left">0.0001</td>
<td align="left">0.04</td>
<td align="left">SOCS3</td>
<td align="left">0.01</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left">CCL20</td>
<td align="left">0.0001</td>
<td align="left">ns</td>
<td align="left">IL22</td>
<td align="left">0.0001</td>
<td align="left">0.04</td>
<td align="left">STAT3</td>
<td align="left">ns</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left">CCL22</td>
<td align="left">0.001</td>
<td align="left">0.005</td>
<td align="left">IL23A</td>
<td align="left">0.0001</td>
<td align="left">0.04</td>
<td align="left">STAT4</td>
<td align="left">0.01</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left">CCL7</td>
<td align="left">ns</td>
<td align="left">ns</td>
<td align="left">IL25</td>
<td align="left">0.0001</td>
<td align="left">ns</td>
<td align="left">STAT5A</td>
<td align="left">ns</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left">CX3CL1</td>
<td align="left">0.001</td>
<td align="left">ns</td>
<td align="left">IL27</td>
<td align="left">0.0001</td>
<td align="left">ns</td>
<td align="left">STAT6</td>
<td align="left">ns</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left">CXCL1</td>
<td align="left">ns</td>
<td align="left">ns</td>
<td align="left">IL3</td>
<td align="left">0.0001</td>
<td align="left">ns</td>
<td align="left">SYK</td>
<td align="left">ns</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left">CXCL12</td>
<td align="left">0.001</td>
<td align="left">ns</td>
<td align="left">IL4</td>
<td align="left">0.0001</td>
<td align="left">ns</td>
<td align="left">TBX21</td>
<td align="left">0.0001</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left">CXCL2</td>
<td align="left">0.001</td>
<td align="left">ns</td>
<td align="left">IL5</td>
<td align="left">0.0001</td>
<td align="left">0.04</td>
<td align="left">TIRAP</td>
<td align="left">0.0001</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left">CXCL5</td>
<td align="left">ns</td>
<td align="left">ns</td>
<td align="left">IL6</td>
<td align="left">0.0001</td>
<td align="left">0.02</td>
<td align="left">TLR4</td>
<td align="left">ns</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left">CXCL6</td>
<td align="left">0.001</td>
<td align="left">ns</td>
<td align="left">TGFβ1</td>
<td align="left">ns</td>
<td align="left">ns</td>
<td align="left">CACYBP</td>
<td align="left">0.04</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left">IL8</td>
<td align="left">ns</td>
<td align="left">ns</td>
<td align="left">TNF</td>
<td align="left">ns</td>
<td align="left">ns</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left" colspan="9">Cytokine Receptors</td>
</tr>
<tr>
<td align="left">IL12RB1</td>
<td align="left">0.0008</td>
<td align="left">0.04</td>
<td align="left">IL7R</td>
<td align="left">ns</td>
<td align="left">ns</td>
<td align="left">IL17RD</td>
<td align="left">0.0001</td>
<td align="left">ns</td>
</tr>
<tr>
<td align="left">IL12RB2</td>
<td align="left">0.001</td>
<td align="left">ns</td>
<td align="left">IL17RB</td>
<td align="left">0.001</td>
<td align="left">ns</td>
<td align="left">IL17RE</td>
<td align="left">0.0002</td>
<td align="left">0.03</td>
</tr>
<tr>
<td align="left">IL23R</td>
<td align="left">0.0002</td>
<td align="left">ns</td>
<td align="left">IL17RC</td>
<td align="left">0.0001</td>
<td align="left">ns</td>
<td align="left">IL6R</td>
<td align="left">0.01</td>
<td align="left">ns</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t005fn001"><p>p value calculated by Student’s t test. ns = non significant, Abbreviations as in legend to <xref ref-type="table" rid="pntd.0004592.t001">Table 1</xref>.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="sec025" sec-type="conclusions">
<title>Discussion</title>
<p>The present study was undertaken with a view to understanding the inflammation/immunopathology seen in patients undergoing episodes of leprosy reactions which are a cause of severe morbidity and nerve damage. Previous studies had shown that Th17 cells formed a third subset in leprosy and were seen in stable leprosy patients in the absence of Th1 and Th2 polarization[<xref ref-type="bibr" rid="pntd.0004592.ref027">27</xref>]. Of interest was the finding that IL-17 and its isomers were up regulated in leprosy reactions as compared to non-reactive leprosy patients. Reaction patients showed higher expression of IL-17A and its isomers as well as associated cytokines IL-21, IL-22 which was further confirmed by ELISA in culture supernatants. Our results are in conformity with a recent study showing increased serum levels of IL-17F in reaction patients[<xref ref-type="bibr" rid="pntd.0004592.ref028">28</xref>]. In conformity with our earlier reports antigen stimulated PBMC of both types of leprosy reactions also showed IL-17 to be present in CD4<sup>+</sup>CCR6<sup>+</sup> cells, along with the signature transcription factor RORC and pSTAT3 [<xref ref-type="bibr" rid="pntd.0004592.ref027">27</xref>]. However, it was of interest to note that there was a difference in the associated cytokines between the two reactions. Increase of IL-17F bearing CCR6<sup>+</sup> cells, was seen in reversal reactions (RR, Type 1) and not in Erythema Nodosum Leprosum (ENL, Type 2) patients. In contrast, CCR6<sup>+</sup> cells bearing IL-21 were increased in ENL but not in RR. It was not possible to determine whether these differences were substantive or related to time kinetics of the human immune responses as it is not possible to clinically determine the time of initiation of the reactional state.</p>
<p>The development of Th17 cells is dependent on several cytokines which may act singly or in synergy with other cytokines [<xref ref-type="bibr" rid="pntd.0004592.ref030">30</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref034">34</xref>]. We next investigated IL-23A, IL-1β and IL-6 which have been implicated in the development and differentiation of Th17 cells [<xref ref-type="bibr" rid="pntd.0004592.ref030">30</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref031">31</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref035">35</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref036">36</xref>]. Our previous studies on stable tuberculoid leprosy had indicated that IL-23 and IL23R but not IL-6 and its receptor (IL-6R) were associated with Th17 cell differentiation[<xref ref-type="bibr" rid="pntd.0004592.ref027">27</xref>]. In the present study IL-6 was significantly increased in both types of leprosy reactions as compared to matching non reactive patients (p &lt;0.01 and 0.001 in RR and ENL respectively) and correlated significantly with STAT3 gene expression (p &lt; 0.03) indicative of the signaling requirements for Th17 cells. The source of IL-6 was found to lie in the monocyte, granulocyte population and the percentage of IL6<sup>+</sup>monocytes were increased in both types of leprosy reaction patients. That monocyte/macrophage family are not only the hosts for the intracellular pathogen <italic>M</italic>.<italic>leprae</italic> but also play a role in the immune responses of the leprosy disease has been shown earlier by us[<xref ref-type="bibr" rid="pntd.0004592.ref037">37</xref>] and others[<xref ref-type="bibr" rid="pntd.0004592.ref038">38</xref>]. IL-6 has been reported to be upregulated in autoimmune diseases [<xref ref-type="bibr" rid="pntd.0004592.ref039">39</xref>].</p>
<p>Using flow cytometry, the present study confirmed the increase in inhibitory FOXP3<sup>+</sup>Treg cells and TGF-β<sup>+</sup> cells in stable non reactive lepromatous leprosy patients[<xref ref-type="bibr" rid="pntd.0004592.ref025">25</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref026">26</xref>] which may be related to the T cell unresponsiveness observed in this form of leprosy. Importantly, Tregs were reduced in lepromatous patients ENL. RR patients also showed relative increase as compared to matching stable BT patients. In both types of reactions, CD4<sup>+</sup>CD25<sup>+</sup> Treg cells showed significant reduction in MFI of FOXP3 in antigen stimulated PBMC of (p&lt;0.02, p&lt;0.003) though qPCR showed an increase in its expression as compared to stable non reactive lepromatous leprosy patients. The variability in FOXP3 expression may be due to whole PBMC included in qPCR studies whereas individual Treg cells were studied by flowcytometry. Alternatively, the results may indicate the transient nature of FOXP3 expression [<xref ref-type="bibr" rid="pntd.0004592.ref025">25</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref040">40</xref>]. The reduction in Treg cells may lower the inhibitory effects and thereby influence the enhanced Th17 activity observed in leprosy reactions. Thus leprosy reactions show an imbalance of Th17 cells and regulatory T cells tipping the balance towards inflammation. Such an imbalance has been reported in tuberculous pleural effusion[<xref ref-type="bibr" rid="pntd.0004592.ref041">41</xref>], respiratory syncytial virus infection in children[<xref ref-type="bibr" rid="pntd.0004592.ref012">12</xref>] and at an early stage of HIV infection where protective CD8<sup>+</sup> cells were noted. In HIV+ patients better clinical status correlated with higher Th17 and lower Treg cells [<xref ref-type="bibr" rid="pntd.0004592.ref013">13</xref>]. Such a perturbation was considered to contribute to the patho-physiology of autoimmune disease[<xref ref-type="bibr" rid="pntd.0004592.ref010">10</xref>]. That Th17 cells may confer protection in tuberculosis by vaccine MVA85A was shown in a murine model[<xref ref-type="bibr" rid="pntd.0004592.ref042">42</xref>].</p>
<p>The development and differentiation pathways of Th17 and Treg cells are influenced by various cytokines. TGF-β along with the pro-inflammatory cytokines IL-6, IL-21 and IL-1β drive naïve T cells towards Th17 differentiation [<xref ref-type="bibr" rid="pntd.0004592.ref043">43</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref044">44</xref>] withIL23 playing a role in stabilizing this population[<xref ref-type="bibr" rid="pntd.0004592.ref031">31</xref>]. TGF-β also drives cells towards FoxP3<sup>+</sup> T regulatory cells and inhibits Th17 differentiation [<xref ref-type="bibr" rid="pntd.0004592.ref009">9</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref019">19</xref>]. IL-6 appears to have a role in determining Th17/Treg balance as along with minimal concentrations of TGF-β it induces Th17 differentiation [<xref ref-type="bibr" rid="pntd.0004592.ref021">21</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref024">24</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref045">45</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref046">46</xref>] and inhibits Treg differentiation. IL-23[<xref ref-type="bibr" rid="pntd.0004592.ref047">47</xref>], CCL20[<xref ref-type="bibr" rid="pntd.0004592.ref048">48</xref>] required for maintenance of Th17 cells and IL23R also showed enhanced expression in leprosy reactions as compared to the respective non reactive groups. IL-21 showed a mixed pattern in flow cytometry, as it was linked to CD4+ cells in RR but not in ENL. When CCR6+ cells were examined IL-21 showed the opposite pattern being associated in ENL and not RR. Taken together, our studies indicate that Th17 cell induction in leprosy reactions is related predominantly to over production of IL-6[<xref ref-type="bibr" rid="pntd.0004592.ref049">49</xref>]combined with low TGF-β.</p>
<p>84 genes defining cell markers, cytokines, chemokines, receptors and signaling molecules were investigated in all 4 clinical groups using qPCR and antigen stimulated PBMC. We confirmed our earlier observations[<xref ref-type="bibr" rid="pntd.0004592.ref027">27</xref>] that stable forms of tuberculoid leprosy showed higher levels of gene expression as compared to anergic lepromatous leprosy. Importantly, the number of genes showing increased expression was higher in RR as compared to ENL subjects. There was some individual variation which may be attributable to the stage of reaction which is difficult to ascertain clinically. The increase in gene expression of cytokines and other markers selectively in Type 1 reactions may be related to the presence of cell mediated immune reactions in tuberculoid leprosy which is the leprosy type of RR patients as compared to ENL who have lepromatous leprosy with negligible T cell functions.</p>
<p>In conclusion, our study shows that the equilibrium between Th17 and Treg cells is disturbed in leprosy reactions with an increase in Th17 cells and reduction in Treg cells. This imbalance is mediated by cytokines as there is concurrent reduction in TGF-β and increase in monocyte derived IL-6. Enhanced Th17 cell activity would explain the inflammation and immuno-pathology associated with leprosy reactions. Furthermore, the increased gene expression of CCL20 and CCL22chemokines in reaction states may facilitate Th17 cell migration to inflammatory sites[<xref ref-type="bibr" rid="pntd.0004592.ref050">50</xref>,<xref ref-type="bibr" rid="pntd.0004592.ref051">51</xref>]. Thus our studies indicate a shift in our understanding of the immunological features that mediate and regulate leprosy reactions with a new paradigm that is beyond the conventional Th1 and Th2 subsets of T cells.</p>
</sec>
<sec id="sec026">
<title>Supporting Information</title>
<supplementary-material id="pntd.0004592.s001" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pntd.0004592.s001" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>Gene accession numbers.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>Drs Vikash, Anupma, and Sandeep Gera of Department of Dermatology, Safdarjung Hospital is gratefully acknowledged.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pntd.0004592.ref001"><label>1</label><mixed-citation publication-type="book" xlink:type="simple"><collab>WHO</collab> (<year>2014</year>) <source>Weekly epidemiological record</source>. <volume>89</volume>: <fpage>389</fpage>–<lpage>400</lpage>.</mixed-citation></ref>
<ref id="pntd.0004592.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ridley</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Jopling</surname> <given-names>WH</given-names></name> (<year>1966</year>) <article-title>Classification of leprosy according to immunity. A five-group system</article-title>. <source>Int J Lepr Other Mycobact Dis</source> <volume>34</volume>: <fpage>255</fpage>–<lpage>273</lpage>. <object-id pub-id-type="pmid">5950347</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref003"><label>3</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Nath</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Chaduvula</surname> <given-names>M</given-names></name> (<year>2010</year>) <chapter-title>Immunological Aspects</chapter-title>. In: <name name-style="western"><surname>Kar</surname> <given-names>HK KB</given-names></name>, editor. <source>IAL Textbook of LEPROSY</source>. <edition>First ed</edition>. <publisher-loc>New Delhi</publisher-loc>: <publisher-name>Jaypee Brothers Medical Publishers (P) Ltd</publisher-name>. pp. <fpage>60</fpage>–<lpage>73</lpage>.</mixed-citation></ref>
<ref id="pntd.0004592.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Modlin</surname> <given-names>RL</given-names></name> (<year>1994</year>) <article-title>Th1-Th2 paradigm: insights from leprosy</article-title>. <source>J Invest Dermatol</source> <volume>102</volume>: <fpage>828</fpage>–<lpage>832</lpage>. <object-id pub-id-type="pmid">8006444</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Misra</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Murtaza</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Walker</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Narayan</surname> <given-names>NP</given-names></name>, <name name-style="western"><surname>Misra</surname> <given-names>RS</given-names></name>, <etal>et al</etal>. (<year>1995</year>) <article-title>Cytokine profile of circulating T cells of leprosy patients reflects both indiscriminate and polarized T-helper subsets: T-helper phenotype is stable and uninfluenced by related antigens of Mycobacterium leprae</article-title>. <source>Immunology</source> <volume>86</volume>: <fpage>97</fpage>–<lpage>103</lpage>. <object-id pub-id-type="pmid">7590888</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Haslett</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Roche</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Butlin</surname> <given-names>CR</given-names></name>, <name name-style="western"><surname>Macdonald</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Shrestha</surname> <given-names>N</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation</article-title>. <source>J Infect Dis</source> <volume>192</volume>: <fpage>2045</fpage>–<lpage>2053</lpage>. <object-id pub-id-type="pmid">16288366</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bjorvatn</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Barnetson</surname> <given-names>RS</given-names></name>, <name name-style="western"><surname>Kronvall</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Zubler</surname> <given-names>RH</given-names></name>, <name name-style="western"><surname>Lambert</surname> <given-names>PH</given-names></name> (<year>1976</year>) <article-title>Immune complexes and complement hypercatabolism in patients with leprosy</article-title>. <source>Clin Exp Immunol</source> <volume>26</volume>: <fpage>388</fpage>–<lpage>396</lpage>. <object-id pub-id-type="pmid">1009681</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Saini</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Prasad</surname> <given-names>HK</given-names></name>, <name name-style="western"><surname>Rani</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Murtaza</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Misra</surname> <given-names>N</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Lsr2 of Mycobacterium leprae and its synthetic peptides elicit restitution of T cell responses in erythema nodosum leprosum and reversal reactions in patients with lepromatous leprosy</article-title>. <source>Clin Vaccine Immunol</source> <volume>20</volume>: <fpage>673</fpage>–<lpage>682</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/CVI.00762-12" xlink:type="simple">10.1128/CVI.00762-12</ext-link></comment> <object-id pub-id-type="pmid">23446220</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sakaguchi</surname> <given-names>S</given-names></name> (<year>2004</year>) <article-title>Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses</article-title>. <source>Annu Rev Immunol</source> <volume>22</volume>: <fpage>531</fpage>–<lpage>562</lpage>. <object-id pub-id-type="pmid">15032588</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eisenstein</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Williams</surname> <given-names>CB</given-names></name> (<year>2009</year>) <article-title>The T(reg)/Th17 cell balance: a new paradigm for autoimmunity</article-title>. <source>Pediatr Res</source> <volume>65</volume>: <fpage>26R</fpage>–<lpage>31R</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1203/PDR.0b013e31819e76c7" xlink:type="simple">10.1203/PDR.0b013e31819e76c7</ext-link></comment> <object-id pub-id-type="pmid">19218879</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Torrado</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Cooper</surname> <given-names>AM</given-names></name> (<year>2010</year>) <article-title>IL-17 and Th17 cells in tuberculosis</article-title>. <source>Cytokine Growth Factor Rev</source> <volume>21</volume>: <fpage>455</fpage>–<lpage>462</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cytogfr.2010.10.004" xlink:type="simple">10.1016/j.cytogfr.2010.10.004</ext-link></comment> <object-id pub-id-type="pmid">21075039</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mangodt</surname> <given-names>TC</given-names></name>, <name name-style="western"><surname>Van Herck</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Nullens</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ramet</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>De Dooy</surname> <given-names>JJ</given-names></name>, <etal>et al</etal>. (<year>2015</year>) <article-title>The role of Th17 and Treg responses in the pathogenesis of RSV infection</article-title>. <source>Pediatr Res</source> <volume>78</volume>: <fpage>483</fpage>–<lpage>491</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/pr.2015.143" xlink:type="simple">10.1038/pr.2015.143</ext-link></comment> <object-id pub-id-type="pmid">26267154</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Falivene</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ghiglione</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Laufer</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Eugenia Socias</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Pia Holgado</surname> <given-names>M</given-names></name>, <etal>et al</etal>. (<year>2015</year>) <article-title>Th17 and Th17/Treg ratio at early HIV infection associate with protective HIV-specific CD8(+) T-cell responses and disease progression</article-title>. <source>Sci Rep</source> <volume>5</volume>: <fpage>11511</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/srep11511" xlink:type="simple">10.1038/srep11511</ext-link></comment> <object-id pub-id-type="pmid">26099972</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bettelli</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Oukka</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kuchroo</surname> <given-names>VK</given-names></name> (<year>2007</year>) <article-title>T(H)-17 cells in the circle of immunity and autoimmunity</article-title>. <source>Nat Immunol</source> <volume>8</volume>: <fpage>345</fpage>–<lpage>350</lpage>. <object-id pub-id-type="pmid">17375096</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Park</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>XO</given-names></name>, <name name-style="western"><surname>Chang</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Nurieva</surname> <given-names>R</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17</article-title>. <source>Nat Immunol</source> <volume>6</volume>: <fpage>1133</fpage>–<lpage>1141</lpage>. <object-id pub-id-type="pmid">16200068</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Curtis</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Way</surname> <given-names>SS</given-names></name> (<year>2009</year>) <article-title>Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens</article-title>. <source>Immunology</source> <volume>126</volume>: <fpage>177</fpage>–<lpage>185</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1365-2567.2008.03017.x" xlink:type="simple">10.1111/j.1365-2567.2008.03017.x</ext-link></comment> <object-id pub-id-type="pmid">19125888</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wenjun Ouyang</surname> <given-names>JKK</given-names></name>, and <name name-style="western"><surname>Yan</surname> <given-names>Zheng</given-names></name> (<year>2004</year>) <article-title>The Biological Functions of T Helper 17 Cell Effector Cytokines in Inflammation</article-title>. <source>Cell Immunity</source> <volume>28</volume>.</mixed-citation></ref>
<ref id="pntd.0004592.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zheng</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Danilenko</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Valdez</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Kasman</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Eastham-Anderson</surname> <given-names>J</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis</article-title>. <source>Nature</source> <volume>445</volume>: <fpage>648</fpage>–<lpage>651</lpage>. <object-id pub-id-type="pmid">17187052</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sakaguchi</surname> <given-names>S</given-names></name> (<year>2008</year>) <article-title>Regulatory T cells in the past and for the future</article-title>. <source>Eur J Immunol</source> <volume>38</volume>: <fpage>901</fpage>–<lpage>937</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/eji.200890012" xlink:type="simple">10.1002/eji.200890012</ext-link></comment> <object-id pub-id-type="pmid">18395855</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bettelli</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Carrier</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Gao</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Korn</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Strom</surname> <given-names>TB</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells</article-title>. <source>Nature</source> <volume>441</volume>: <fpage>235</fpage>–<lpage>238</lpage>. <object-id pub-id-type="pmid">16648838</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Anderson</surname> <given-names>DE</given-names></name>, <name name-style="western"><surname>Baecher-Allan</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Hastings</surname> <given-names>WD</given-names></name>, <name name-style="western"><surname>Bettelli</surname> <given-names>E</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>IL-21 and TGF-beta are required for differentiation of human T(H)17 cells</article-title>. <source>Nature</source> <volume>454</volume>: <fpage>350</fpage>–<lpage>352</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature07021" xlink:type="simple">10.1038/nature07021</ext-link></comment> <object-id pub-id-type="pmid">18469800</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhou</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Lopes</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>Chong</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Ivanov</surname> <given-names>II</given-names></name>, <name name-style="western"><surname>Min</surname> <given-names>R</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function</article-title>. <source>Nature</source> <volume>453</volume>: <fpage>236</fpage>–<lpage>240</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature06878" xlink:type="simple">10.1038/nature06878</ext-link></comment> <object-id pub-id-type="pmid">18368049</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Korn</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Bettelli</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Gao</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Awasthi</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Jager</surname> <given-names>A</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells</article-title>. <source>Nature</source> <volume>448</volume>: <fpage>484</fpage>–<lpage>487</lpage>. <object-id pub-id-type="pmid">17581588</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhou</surname> <given-names>L</given-names></name> (<year>2007</year>) <article-title>IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways</article-title>. <source>Nat Immunol</source> <volume>8</volume>:<fpage>967</fpage>–<lpage>974</lpage>. <object-id pub-id-type="pmid">17581537</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Saini</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Ramesh</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Nath</surname> <given-names>I</given-names></name> (<year>2014</year>) <article-title>Increase in TGF-beta secreting CD4(+)CD25(+) FOXP3(+) T regulatory cells in anergic lepromatous leprosy patients</article-title>. <source>PLoS Negl Trop Dis</source> <volume>8</volume>: <fpage>e2639</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pntd.0002639" xlink:type="simple">10.1371/journal.pntd.0002639</ext-link></comment> <object-id pub-id-type="pmid">24454972</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bobosha</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Wilson</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>van Meijgaarden</surname> <given-names>KE</given-names></name>, <name name-style="western"><surname>Bekele</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Zewdie</surname> <given-names>M</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>T-cell regulation in lepromatous leprosy</article-title>. <source>PLoS Negl Trop Dis</source> <volume>8</volume>: <fpage>e2773</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pntd.0002773" xlink:type="simple">10.1371/journal.pntd.0002773</ext-link></comment> <object-id pub-id-type="pmid">24722473</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Saini</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Ramesh</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Nath</surname> <given-names>I</given-names></name> (<year>2013</year>) <article-title>CD4+ Th17 cells discriminate clinical types and constitute a third subset of non Th1, Non Th2 T cells in human leprosy</article-title>. <source>PLoS Negl Trop Dis</source> <volume>7</volume>: <fpage>e2338</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pntd.0002338" xlink:type="simple">10.1371/journal.pntd.0002338</ext-link></comment> <object-id pub-id-type="pmid">23936569</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sundeep Chaitanya</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Ravindra</surname> <given-names>P</given-names></name>. <name name-style="western"><surname>Turankar</surname></name>, <name name-style="western"><surname>Karri</surname> <given-names>Samuel Raj</given-names></name> &amp; <name name-style="western"><surname>Sengupta</surname> <given-names>U.</given-names></name> (<year>2012</year>) <article-title>Increased Serum Circulatory Levels of Interleukin 17F in Type 1 Reactions of Leprosy</article-title>. <source>J Clin Immunol</source>.</mixed-citation></ref>
<ref id="pntd.0004592.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ridley</surname> <given-names>DS</given-names></name> (<year>1969</year>) <article-title>Reactions in leprosy</article-title>. <source>Lepr Rev</source> <volume>40</volume>: <fpage>77</fpage>–<lpage>81</lpage>. <object-id pub-id-type="pmid">5792378</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Acosta-Rodriguez</surname> <given-names>EV</given-names></name>, <name name-style="western"><surname>Napolitani</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Lanzavecchia</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Sallusto</surname> <given-names>F</given-names></name> (<year>2007</year>) <article-title>Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells</article-title>. <source>Nat Immunol</source> <volume>8</volume>: <fpage>942</fpage>–<lpage>949</lpage>. <object-id pub-id-type="pmid">17676045</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Aggarwal</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ghilardi</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Xie</surname> <given-names>MH</given-names></name>, <name name-style="western"><surname>de Sauvage</surname> <given-names>FJ</given-names></name>, <name name-style="western"><surname>Gurney</surname> <given-names>AL</given-names></name> (<year>2003</year>) <article-title>Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17</article-title>. <source>J Biol Chem</source> <volume>278</volume>: <fpage>1910</fpage>–<lpage>1914</lpage>. <object-id pub-id-type="pmid">12417590</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Geluk</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>van Meijgaarden</surname> <given-names>KE</given-names></name>, <name name-style="western"><surname>Wilson</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Bobosha</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>van der Ploeg-van Schip</surname> <given-names>JJ</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>Longitudinal immune responses and gene expression profiles in type 1 leprosy reactions</article-title>. <source>J Clin Immunol</source> <volume>34</volume>: <fpage>245</fpage>–<lpage>255</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10875-013-9979-x" xlink:type="simple">10.1007/s10875-013-9979-x</ext-link></comment> <object-id pub-id-type="pmid">24370984</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Rohowsky-Kochan</surname> <given-names>C</given-names></name> (<year>2008</year>) <article-title>Regulation of IL-17 in human CCR6+ effector memory T cells</article-title>. <source>J Immunol</source> <volume>180</volume>: <fpage>7948</fpage>–<lpage>7957</lpage>. <object-id pub-id-type="pmid">18523258</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McGeachy</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Cua</surname> <given-names>DJ</given-names></name> (<year>2008</year>) <article-title>Th17 cell differentiation: the long and winding road</article-title>. <source>Immunity</source> <volume>28</volume>: <fpage>445</fpage>–<lpage>453</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.immuni.2008.03.001" xlink:type="simple">10.1016/j.immuni.2008.03.001</ext-link></comment> <object-id pub-id-type="pmid">18400187</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Volpe</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Servant</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Zollinger</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Bogiatzi</surname> <given-names>SI</given-names></name>, <name name-style="western"><surname>Hupe</surname> <given-names>P</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses</article-title>. <source>Nat Immunol</source> <volume>9</volume>: <fpage>650</fpage>–<lpage>657</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ni.1613" xlink:type="simple">10.1038/ni.1613</ext-link></comment> <object-id pub-id-type="pmid">18454150</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wilson</surname> <given-names>NJ</given-names></name>, <name name-style="western"><surname>Boniface</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Chan</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>McKenzie</surname> <given-names>BS</given-names></name>, <name name-style="western"><surname>Blumenschein</surname> <given-names>WM</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Development, cytokine profile and function of human interleukin 17-producing helper T cells</article-title>. <source>Nat Immunol</source> <volume>8</volume>: <fpage>950</fpage>–<lpage>957</lpage>. <object-id pub-id-type="pmid">17676044</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nath</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Saini</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Valluri</surname> <given-names>VL</given-names></name> (<year>2015</year>) <article-title>Immunology of leprosy and diagnostic challenges</article-title>. <source>Clin Dermatol</source> <volume>33</volume>: <fpage>90</fpage>–<lpage>98</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.clindermatol.2014.07.005" xlink:type="simple">10.1016/j.clindermatol.2014.07.005</ext-link></comment> <object-id pub-id-type="pmid">25432814</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Scollard</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Adams</surname> <given-names>LB</given-names></name>, <name name-style="western"><surname>Gillis</surname> <given-names>TP</given-names></name>, <name name-style="western"><surname>Krahenbuhl</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Truman</surname> <given-names>RW</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>The continuing challenges of leprosy</article-title>. <source>Clin Microbiol Rev</source> <volume>19</volume>: <fpage>338</fpage>–<lpage>381</lpage>. <object-id pub-id-type="pmid">16614253</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Oukka</surname> <given-names>M</given-names></name> (<year>2008</year>) <article-title>Th17 cells in immunity and autoimmunity</article-title>. <source>Ann Rheum Dis</source> <volume>67</volume> <issue>Suppl 3</issue>: <fpage>iii26</fpage>–<lpage>29</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/ard.2008.098004" xlink:type="simple">10.1136/ard.2008.098004</ext-link></comment> <object-id pub-id-type="pmid">19022809</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ioan-Facsinay</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>van der Voort</surname> <given-names>EI</given-names></name>, <name name-style="western"><surname>Huizinga</surname> <given-names>TW</given-names></name>, <name name-style="western"><surname>Toes</surname> <given-names>RE</given-names></name> (<year>2007</year>) <article-title>Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells</article-title>. <source>Eur J Immunol</source> <volume>37</volume>: <fpage>129</fpage>–<lpage>138</lpage>. <object-id pub-id-type="pmid">17154262</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ye</surname> <given-names>ZJ</given-names></name>, <name name-style="western"><surname>Zhou</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Du</surname> <given-names>RH</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>B</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Imbalance of Th17 cells and regulatory T cells in tuberculous pleural effusion</article-title>. <source>Clin Vaccine Immunol</source> <volume>18</volume>: <fpage>1608</fpage>–<lpage>1615</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/CVI.05214-11" xlink:type="simple">10.1128/CVI.05214-11</ext-link></comment> <object-id pub-id-type="pmid">21813663</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Monin</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Griffiths</surname> <given-names>KL</given-names></name>, <name name-style="western"><surname>Slight</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Rangel-Moreno</surname> <given-names>J</given-names></name>, <etal>et al</etal>. (<year>2015</year>) <article-title>Immune requirements for protective Th17 recall responses to Mycobacterium tuberculosis challenge</article-title>. <source>Mucosal Immunol</source> <volume>8</volume>: <fpage>1099</fpage>–<lpage>1109</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/mi.2014.136" xlink:type="simple">10.1038/mi.2014.136</ext-link></comment> <object-id pub-id-type="pmid">25627812</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Annunziato</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Cosmi</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Liotta</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Maggi</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Romagnani</surname> <given-names>S</given-names></name> (<year>2008</year>) <article-title>The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation</article-title>. <source>Int Immunol</source> <volume>20</volume>: <fpage>1361</fpage>–<lpage>1368</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/intimm/dxn106" xlink:type="simple">10.1093/intimm/dxn106</ext-link></comment> <object-id pub-id-type="pmid">18820263</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kimura</surname> <given-names>Akihiro</given-names></name>, <name name-style="western"><surname>Kishimoto</surname> <given-names>T</given-names></name> (<year>2010</year>) <article-title>IL-6: Regulator of Treg/Th17 balance</article-title>. <source>Eur J Immunol</source> <volume>40</volume>: <fpage>1830</fpage>–<lpage>1835</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/eji.201040391" xlink:type="simple">10.1002/eji.201040391</ext-link></comment> <object-id pub-id-type="pmid">20583029</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Deenick</surname> <given-names>EK</given-names></name>, <name name-style="western"><surname>Tangye</surname> <given-names>SG</given-names></name> (<year>2007</year>) <article-title>Autoimmunity: IL-21: a new player in Th17-cell differentiation</article-title>. <source>Immunol Cell Biol</source> <volume>85</volume>: <fpage>503</fpage>–<lpage>505</lpage>. <object-id pub-id-type="pmid">17768419</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McGeachy</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Bak-Jensen</surname> <given-names>KS</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Tato</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Blumenschein</surname> <given-names>W</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology</article-title>. <source>Nat Immunol</source> <volume>8</volume>: <fpage>1390</fpage>–<lpage>1397</lpage>. <object-id pub-id-type="pmid">17994024</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stritesky</surname> <given-names>GL</given-names></name>, <name name-style="western"><surname>Yeh</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Kaplan</surname> <given-names>MH</given-names></name> (<year>2008</year>) <article-title>IL-23 promotes maintenance but not commitment to the Th17 lineage</article-title>. <source>J Immunol</source> <volume>181</volume>: <fpage>5948</fpage>–<lpage>5955</lpage>. <object-id pub-id-type="pmid">18941183</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Laumonnier</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Syrovets</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Simmet</surname> <given-names>T</given-names></name> (<year>2013</year>) <article-title>Recruitment of CCR6-expressing Th17 cells by CCL20 secreted from plasmin-stimulated macrophages</article-title>. <source>Acta Biochim Biophys Sin (Shanghai)</source> <volume>45</volume>: <fpage>593</fpage>–<lpage>600</lpage>.</mixed-citation></ref>
<ref id="pntd.0004592.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stefani</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Guerra</surname> <given-names>JG</given-names></name>, <name name-style="western"><surname>Sousa</surname> <given-names>AL</given-names></name>, <name name-style="western"><surname>Costa</surname> <given-names>MB</given-names></name>, <name name-style="western"><surname>Oliveira</surname> <given-names>ML</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Potential plasma markers of Type 1 and Type 2 leprosy reactions: a preliminary report</article-title>. <source>BMC Infect Dis</source> <volume>9</volume>: <fpage>75</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2334-9-75" xlink:type="simple">10.1186/1471-2334-9-75</ext-link></comment> <object-id pub-id-type="pmid">19473542</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ghannam</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Dejou</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Pedretti</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Giot</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Dorgham</surname> <given-names>K</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>CCL20 and beta-defensin-2 induce arrest of human Th17 cells on inflamed endothelium in vitro under flow conditions</article-title>. <source>J Immunol</source> <volume>186</volume>: <fpage>1411</fpage>–<lpage>1420</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4049/jimmunol.1000597" xlink:type="simple">10.4049/jimmunol.1000597</ext-link></comment> <object-id pub-id-type="pmid">21178014</object-id></mixed-citation></ref>
<ref id="pntd.0004592.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eriksson</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Andersson</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Cassel</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Nystrom</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ernerudh</surname> <given-names>J</given-names></name> (<year>2015</year>) <article-title>Increase in Th17-associated CCL20 and decrease in Th2-associated CCL22 plasma chemokines in active ANCA-associated vasculitis</article-title>. <source>Scand J Rheumatol</source> <volume>44</volume>: <fpage>80</fpage>–<lpage>83</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3109/03009742.2014.952332" xlink:type="simple">10.3109/03009742.2014.952332</ext-link></comment> <object-id pub-id-type="pmid">25352172</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>